Universal Time: 06:20  |  Local Time: 06:20 (3h GMT)
Select your timezone:
Room: H8-01-D

111.2 Biocompatibility of genetically-engineered pig cornea in corneal xenotransplantation for the use of human clinical trials

Chung Young Kim, Korea

Clinical Assistant Professor
Department of Ophthalmology
Seoul National University Hospital

Abstract

Biocompatibility of genetically-engineered pig cornea in corneal xenotransplantation for the use of human clinical trials

Chung Young Kim1,2, Seung Hyeun Lee2,3, Jin Suk Ryu2, Dong Hee Choi2, Chang Ho Yoon1,2, Chung-Gyu Park4,5, Joohyun Shim6, Hyunil Kim6, Mee Kum Kim1,2,4.

1Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea; 2Laboratory of Ocular Regenerative Medicine and Immunology, Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea; 3Department of Ophthalmology, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, Korea; 4Transplantation Research Institute, Seoul National University College of Medicine, Seoul, Korea; 5Department of Microbiology and Immunology, Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea; 6Optipharm, Inc., Cheongju, Korea

Introduction: Corneal xenotransplantation, first attempted in the 19th century, was historically hindered by xenogeneic immune barriers. With the advent of alpha-1,3-galactosyltransferase gene-knockout pigs and CRISPR-Cas9-mediated multi-gene editing—including PERV inactivation—xenotransplantation has re-emerged as a viable clinical strategy. Given the persistent shortage of donor corneas in East Asia, porcine corneas are under investigation as alternative graft sources. While early genetically-engineered (GE) models showed limited graft survival without substantial immunosuppression, multi-gene-edited pigs are being developed to address this. However, the impact of extensive immune-related gene editing on corneal endothelial cell function remains unknown. This study assesses the biophysical integrity of endothelial cells in these multi-gene-edited porcine corneas, a critical determinant for their clinical applicability in full-thickness xenotransplantation.
Methods: Triple or quadruple knockout (T[Q]KO) pigs with targeted deletions in GGTA1, CMAH, β4GalNT2, and/or iGb3s were utilized, combined with knock-in (KI) or overexpression (OE) of human CD55, CD39, CD46, and thrombomodulin (TBM) genes. A total of 27 eyes from 14 genetically engineered pigs were analyzed to assess physical and functional suitability as corneal donors. Corneal endothelial cell density (ECD) was monitored over 7 days in storage medium. Endothelial cell proliferative capacity was assessed via doubling time (DT), and immunofluorescence was used to evaluate expression of endothelial pump and tight junction proteins.
Results: The GE pigs had a mean age of 11.9 months, with an average central corneal thickness of 718.2 μm. ECD loss was significantly greater in pigs under 6 months old (55.1%) compared to those over 6 months (8.8%) (p<0.001). T(Q)KO/hCD46OE/hTBMOE corneas exhibited early endothelial apoptosis or necrosis, whereas other GE corneas did not show such changes. Although DT was increased across all GE pigs, there was no age-related difference. Key endothelial markers (ZO-1, N-cadherin, ATPase, SLC4A1, and aquaporin 1) were consistently expressed across all GE variants.
Conclusion: These findings suggest that corneas from both T(Q)KO/hCD55KI/hCD39KI and QKO pigs over 6 months of age exhibit sufficient endothelial cell function, making them suitable donor candidates for human corneal xenotransplantation.

© 2025 IXA 2025